Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Apr 2018

Schreck Karisa C, Guajardo Andrew, Lin Doris D M, Eberhart Charles G, Grossman Stuart A

Abstract excerpt

BRAF V600 mutations are being identified in patients with primary brain tumors more often as molecular testing becomes widely available. Targeted treatment with BRAF inhibitors has been attempted in individual cases with some responses, whereas others showed no response or developed resistance. Preclinical work suggests that gliomas could be more responsive to the concurrent use of BRAF and MEK inhibition for MAP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Magnetic Resonance Imaging

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 29632053
DOI: 10.6004/jnccn.2017.7052

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.PMID 29632053Read ↗

Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.Semantic proximity Read ↗

Dabrafenib and trametinib in BRAFV600E mutated glioma.Semantic proximity Read ↗

BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.Semantic proximity Read ↗

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain TumorsSemantic proximity Read ↗

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsSemantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.Semantic proximity Read ↗

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.Semantic proximity Read ↗

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.Semantic proximity Read ↗

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.Semantic proximity Read ↗

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.Semantic proximity Read ↗

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.